Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Sozinibercept's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Sozinibercept. Showing past 6 months and next 12 months · 5 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Sozinibercept | Opthea | Fc Fusion Protein | — | 0 | ||||
| Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals | Faculty Hospital Kralovske Vinohrady | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting | Medical University of Vienna | — | Phase 4 | — | — | — | — | — |
| Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) | Parc de Salut Mar | — | Phase 3 | — | — | — | — | — |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Kodiak Sciences Inc | — | Phase 3 | — | — | — | — | — |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | EyePoint Pharmaceuticals, Inc. | — | Phase 3 | — | — | — | — | — |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | AbbVie | — | Phase 3 | — | — | — | — | — |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | EyePoint Pharmaceuticals, Inc. | — | Phase 3 | — | — | — | — | — |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Adverum Biotechnologies, Inc. | — | Phase 3 | — | — | — | — | — |
| High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM) | Clinique de Retine de l'est | — | Phase 3 | — | — | — | — | — |
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 4D Molecular Therapeutics | — | Phase 3 | — | — | — | — | — |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) | Adverum Biotechnologies, Inc. | — | Phase 3 | — | — | — | — | — |
| A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders | Outlook Therapeutics, Inc. | — | Phase 3 | — | — | — | — | — |
| Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) | Innostellar Biotherapeutics Co.,Ltd | — | Phase 3 | — | — | — | — | — |
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 4D Molecular Therapeutics | — | Phase 3 | — | — | — | — | — |
| Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). | King's College Hospital NHS Trust | — | Phase 3 | — | — | — | — | — |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | AbbVie | — | PHASE2/PHASE3 | — | — | — | — | — |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | EyeBiotech Ltd. | — | PHASE2/PHASE3 | — | — | — | — | — |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) | EyeBiotech Ltd. | — | PHASE2/PHASE3 | — | — | — | — | — |
| This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B. | Shenzhen Oculgen Biomedical Technology Co., Ltd. | — | PHASE2/PHASE3 | — | — | — | — | — |
| Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] | Adverum Biotechnologies, Inc. | — | Phase 2 | — | — | — | — | — |
| Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME | Ashvattha Therapeutics, Inc. | — | Phase 2 | — | — | — | — | — |
| Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy | Sam Chun Dang Pharm. Co. Ltd. | — | Phase 2 | — | — | — | — | — |
| RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | AbbVie | — | Phase 2 | — | — | — | — | — |
| Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD | Beijing Anlong Biopharmaceutical Co., Ltd. | — | Phase 2 | — | — | — | — | — |
| A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | Novartis Pharmaceuticals | — | Phase 2 | — | — | — | — | — |
| MMP-9 Inhibition for Recalcitrant Wet AMD | University of Iowa | — | Phase 2 | — | — | — | — | — |
| Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | AbbVie | — | Phase 2 | — | — | — | — | — |
| Gene Therapy(FT-003) for Wet AMD | Frontera Therapeutics | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD | Beijing Anlong Biopharmaceutical Co., Ltd. | — | PHASE1/PHASE2 | — | — | — | — | — |
| NT-101 Topical Ophthalmic Solution in Patients With Wet AMD | NexThera Co., Ltd. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) | Skyline Therapeutics (US) Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration | Elisigen, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) | Avirmax Biopharma Inc | — | PHASE1/PHASE2 | — | — | — | — | — |
| 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | 4D Molecular Therapeutics | — | PHASE1/PHASE2 | — | — | — | — | — |
| Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD | Guangzhou Jiayin Biotech Ltd | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD) | Fujian Haixi Pharmaceuticals Co., Ltd. | — | PHASE1/PHASE2 | — | — | — | — | — |